150 09/367629 16ci 1641

PATENT COOPERATION TREATY

PCT

REC'D 17 JAN 2000

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

FOR FURTHER ACTION	See Notifi Preliminary	cation of Transmittal Examination Report (Fo	of International rm PCT/IPEA/416)
International filing date (day/m	onth/year)	Priority date (day/mon	th/year)
06 AUGUST 1998		07 AUGUST 1997	
or national classification and IPC			
s transmitted to the applicant a total of sheets. mpanied by ANNEXES, i.e., she the basis for this report and/or sh	ets of the des	cription, claims and/or do	rawings which have
//	instructions		_
	tems:		RECEIVE
ort			TEB 0 8 2000
			2 2000
ent of report with regard to no	velty, inven	tive step or industrial	applicability
			•
ent under Article 35(2) with reg	gard to novel	y, inventive step or ind	ustrial applicability;
ts cited			
	tion		
Date	e of completion	on of this report	
	02 DECEMB	ER 1999	
	norized office		M
iemarks	MARY E. M	OSHER, PH.D.	
1	phone No.	(703) 308-0196	4-
	International filing date (day/m) 06 AUGUST 1998 or national classification and IPC mary examination report has stransmitted to the applicant a total of sheets. Impanied by ANNEXES, i.e., sheethe basis for this report and/or sheetion 607 of the Administrative total of sheets. In a total of sheets sheets sheets sheets sheets sheets. In a total of sheets sheets sheets sheets sheets sheets sheets. In a total of sheets sheets sheets sheets sheets sheets sheets sheets. In a total of sheets she	International filing date (day/month/year) 06 AUGUST 1998 or national classification and IPC mary examination report has been preparate transmitted to the applicant according to a total of	International filing date (day/month/year) Of AUGUST 1998 Or national classification and IPC The preliminary examination report has been prepared by this Internation is transmitted to the applicant according to Article 36. The presentation of the Administrative Instructions under the PCT). The presentation of the Administrative Instructions under the PCT). The presentation of the Administrative Instructions under the PCT). The presentation of the Administrative Instructions under the PCT). The presentation of the Administrative Instructions under the PCT). The presentation of the Administrative Instructions under the PCT). The presentation of the Administrative Instructions under the PCT). The presentation of the PCT of the Administrative Instructions under the PCT. The presentation of the PCT of the Administrative Instructions under the PCT. The presentation of the PCT of the Administrative Instructions under the PCT. The presentation of the PCT of the Administrative Instructions under the PCT. The presentation of the PCT of the Administrative Instructions under the PCT. The presentation of the PCT of the Administrative Instructions under the PCT. The presentation of the PCT of the Administrative Instructions under the PCT. The presentation of the PCT of the

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US98/16383

L Basis of	the report		
1. This report he	as been drawn on the	basis of (Substitute sheets wh this report as "originally filed	sich have been furnished to the receiving Office in response to an invitation " and are not annexed to the report since they do not contain amendments):
[X]		al application as origina	1
_ [X]	the description,	pages 1-31	_ , as originally filed.
ليا	•		, filed with the demand.
		pages NONE	_ , filed with the letter of
		pages	_ , filed with the letter of
x	the claims,	Nos. <u>1-50</u>	, as originally filed.
ت	•	Nos. NONE	, as amended under Article 19.
		Nos. NONE	, filed with the demand.
			, filed with the letter of
		Nos	, filed with the letter of
x	the drawings,	sheets /fig none	, as originally filed.
ر ک	-	sheets/fig NONE	, filed with the demand.
			, filed with the letter of
		sheets /fig	, filed with the letter of
	٠.		
2. The amer	ndments have resul	ted in the cancellation o	f:
x	the description	, pages none	
×		Nos. none	
[x		sheets/fig none	
	J		
3. T	his report has been	established as if (some of)	the amendments had not been made, since they have been considered
	go beyond the disc	losure as filed, as indicated	d in the Supplemental Box Additional observations below (Rule 70.2(c)).
4 4 4 4 4 4 4 4	nal observations,	if necessary	
NONE	nai observations,	ii necessary.	
NONE			

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/16383

Novelty (N) Claims 1-43, 47-50 YI Claims 44-46	Novelty (N) Claims Claims 44-46 Inventive Step (IS) Claims Claims 1-43, 47-50 Claims 1-44-46 Industrial Applicability (IA) Claims Claims 1-50 Claims Cl	Citations and explanations supported	g such statem	d to novelty, inventive step or indus nt	
Inventive Step (IS) Claims Claims 1-43, 47-50 Claims 44-46 Industrial Applicability (IA) Claims Claims 1-50 Claims 1-50 Claims No Claims Claims Claims 1-50 Claims No Claims No Claims Claims 1-50 Claims No Claims No Claims Claims 1-50 Claims No Claims No Claims 1-43 and 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since thes claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS NEW CITATIONS NEW CITATIONS	Inventive Step (IS) Claims Claims 1-43, 47-50 Claims 44-46 Industrial Applicability (IA) Claims Claims 1-50 Claims 1-50 Claims No Claims Claims Claims Claims 1-50 Claims No Claims Clai	STATEMENT			
Inventive Step (IS) Claims 1-43, 47-50 YI Claims 44-46 No Industrial Applicability (IA) Claims 1-50 YY Claims 1-50 YY Claims 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since thes claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS ————————————————————————————————————	Inventive Step (IS) Claims 1-43, 47-50 YI Claims 44-46 No Industrial Applicability (IA) Claims 1-50 YI Claims none CITATIONS AND EXPLANATIONS Claims 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since thes claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS ————————————————————————————————————	Novelty (N)	Claims	1-43, 47-50	YI
Industrial Applicability (IA) Claims	Industrial Applicability (IA) Claims	, ,	Claims	44-46	NO
Industrial Applicability (IA) Claims	Industrial Applicability (IA) Claims	Inventive Step (IS)	Claims	1-43, 47-50	YI
Claims none Claims none N Claims none N Claims 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since thes claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS ————————————————————————————————————	Claims none Claims none No. Claims none No. Claims 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since thes claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS		Claims	44-46	NO
Claims none Claims none N Claims none N Claims 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since thes claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS ————————————————————————————————————	Claims none Claims none No. Claims none No. Claims 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since thes claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS				V
Claims 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since thes claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS ————————————————————————————————————	Claims 44-46 lack novelty under PCT Article 33(2) as being anticipated by Apatate® vitamin concentrate, as shown in the 199 Physician's Desk Reference (PDR). Although the PDR does not teach the same intended use for the concentrate, the reference concentrate has the same ingredients as recited in the claims, and is capable of being used for the same purpose. Since these claims are drawn to a composition, not a method of use, the reference concentrate meets each and every claim limitation. Claims 1-43 and 47-50 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest supplementation of dialysate solution with the components listed in the claims. Claims 1-50 meet the criteria set out in PCT article 33(4) for industrial applicability. NEW CITATIONS ————————————————————————————————————	Industrial Applicability (IA)			N
		Physician's Desk Reference (PDR). Althouge concentrate has the same ingredients as reclaims are drawn to a composition, not a management of the criteria set suggest supplementation of dialysate solution. Claims 1-50 meet the criteria set out in PC	the PDR does ited in the claim tethod of use, the tout in PCT Article with the compart on with the compart article 33(4) for	not teach the same intended use for the cor, and is capable of being used for the sam reference concentrate meets each and ever cle 33(2)-(3), because the prior art does no onents listed in the claims.	ncentrate, the reference ne purpose. Since thes ry claim limitation.
		NONE			
in the second of		NONE			

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/16383

Supplemental Box (To be used when the space in any of the preceding boxes is not sufficient)						
Continuation of: Boxes I - VIII	Sheet 10					
CLASSIFICATION: The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(6): A61M 1/14, 1/28; A61K 31/00, 31/44, 31/51, 31/68 and US Cl.: 210/645, 646; 604/29; 514/52,42	9,276					
	ā.					
	•					
	•					

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

	From th	ne INTERNATIONAL E	BUREAU
PCT	To:		
NOTIFICATION OF THE RECORDING OF A CHANGE (PCT Rule 92bis.1 and Administrative Instructions, Section 422) Date of mailing (day/month/year) 11 June 1999 (11.06.99)	MONACO, Daniel, A. Seidel, Gonda, Lavorgna & Monaco, P.C. Suite 1800 Two Penn Center Plaza Philadelphia, PA 19102 ÉTATS-UNIS D'AMÉRIQUE		
Applicant's or agent's file reference 9403-2 PC		IMPORTANT NOT	TIFICATION
International application No. PCT/US98/16383		nal filing date (day/month/ .ugust 1998 (06.08.98)	, ,
The following indications appeared on record concerning: X the applicant X the inventor	the ager	t the comm	non representative
Name and Address		State of Nationality	State of Residence
GUPTA, Ajay 39151 Horton Drive Farmington Hills, MI 48331 United States of America		Telephone No.	US
		Teleprinter No.	
2. The International Bureau hereby notifies the applicant that th	e following	change has been recorded	I concerning:
the person the name the add	ress	X the nationality	the residence
Name and Address		State of Nationality	State of Residence
GUPTA, Ajay 39151 Horton Drive Farmington Hills, MI 48331 United States of America		IN Telephone No.	US
		Facsimile No.	
		Teleprinter No.	

Dominique DELMAS

Telephone No.: (41-22) 338.83.38

United States of America	
	Facsimile No.
	Teleprinter No.
3. Further observations, if necessary:	
4. A copy of this notification has been sent to:	·
X the receiving Office	the designated Offices concerned
the International Searching Authority	X the elected Offices concerned
X the International Preliminary Examining Authority	other:
The International Bureau of WIPO	Authorized officer
The international buleau of WIFO	

Facsimile No.: (41-22) 740.14.35

34, chemin des Colombettes

1211 Geneva 20, Switzerland

From t	he l	NT	FRN	ΔΤΙ	ONA	A I	LIRE	ΔI

PCT	То:
NOTIFICATION OF ELECTION (PCT Rule 61.2)	United States Patent and Trademark Office (Box PCT) Crystal Plaza 2 Washington, DC 20231 ÉTATS-UNIS D'AMÉRIQUE
Date of mailing (day/month/year) 10 May 1999 (10.05.99)	in its capacity as elected Office
International application No. PCT/US98/16383	Applicant's or agent's file reference 9403-2 PC
International filing date (day/month/year) 06 August 1998 (06.08.98)	Priority date (day/month/year) 07 August 1997 (07.08.97)
Applicant GUPTA, Ajay	
1. The designated Office is hereby notified of its election made X in the demand filed with the International Preliminary 29 January 195 in a notice effecting later election filed with the Intern 2. The election X was was not was not was not Rule 32.2(b).	Examining Authority on: 99 (29.01.99) ational Bureau on: late or, where Rule 32 applies, within the time limit under
The International Bureau of WIPO	Authorized officer

Sean Taylor

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35

34, chemin des Colombettes

1211 Geneva 20, Switzerland

10 Rec'd PCT/PTO 1 9 AUG 1999

The PTO did not receive the following isted from(s)
NO POST CARCU

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/16383

IPC(6) US CL According t B. FIEL Minimum d U.S. :	SSIFICATION OF SUBJECT MATTER :A61M 1/14, 1/28; A61K 31/00, 31/44, 31/51, 31/68 :210/645, 646; 604/29; 514/52,429,276 to International Patent Classification (IPC) or to both a DS SEARCHED locumentation searched (classification system followed 210/645, 646; 604/29; 514/52,429,276 tion searched other than minimum documentation to the	d by classification symbols)	in the fields searched					
	Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.							
C. DOC	CUMENTS CONSIDERED TO BE RELEVANT							
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.					
x	Physicians' Desk Reference. 1996. Pag see entire document.	ge 1319, see Apatate [®] liquid,	44-46					
A	US 5,108,767 A (MULCHANDANI et al.) 28 April 1992. 1-43, 47-50							
A	BOSTOM et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney International. January 1996. Vol. 49, pages 147-152.							
A	KASAMA et al. Vitamin B6 and Hemodialysis: The Impact of High-Flux/High Efficiency Dialysis and Review of the Literature. American Journal of Kidney Diseases. May 1996. Vol. 27, Number 5, pages 680-686.							
Further documents are listed in the continuation of Box C. See patent family annex.								
A do	necial categories of cited documents: ocument defining the general state of the art which is not considered be of particular relevance	*T* later document published after the inte date and not in conflict with the appli the principle or theory underlying the	lication but cited to understand					
	rlier document published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be considered when the document is taken alone						
cit sp "O" do	cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is							
	neument published prior to the international filing date but later than e priority date claimed	*&* document member of the same paten	t family					
	actual completion of the international search	Date of mailing of the international sea	arch report					
Name and a Commission Box PCT	mailing address of the ISA/US oner of Patents and Trademarks	Authorized officed MARY E. MOSHER, PH.D.	Wete (8)					
Washingto Facsimile N	n, D.C. 20231 No. (703) 305-3230	Telephone No. (703) 308-0196	,					





International application No. PCT/US98/16383

B. FIELDS SEARCHED Electronic data bases consulted (Name of data base and where practicable terms used):							
APS, Medline, Derwent World Pater solutions, nutrient#, nutrition###,	APS, Medline, Derwent World Patents. Search terms: Dialysis, hemodialysis, peritone?, vitamin#, dialysate, solution, solutions, nutrient#, nutrition###, folic, folate, b6, thiamin#, b12, pyridox?, ?cobalamin, supplement?						
			•				